HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
NTLA
Intellia Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.52B
Market Cap
$1.52B
Enterprise Val
$1.23B
P/E Ratio
-3.86
P/B Ratio
2.45
Trailing PEG (1Y)
0.15
As Of
Jun 8, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$620.9M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-57.27%
Return on Assets-46.08%
Current Ratio6.10
Debt/Equity0.13
LT Debt/Equity0.10
Revenue Per Share0.13

Income Statement

Mar 31, 2026
Revenue$15.0M
Cost of Revenue$0.00
Gross Profit$15.0M
R&D$80.7M
SG&A$34.8M
Operating Expenses$115.6M
Operating Income-$100.5M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$96.2M
EPS (Basic)$-0.81
EPS (Diluted)$-0.81
EBIT-$96.2M
EBITDA-$94.0M
Consolidated Income-$96.2M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$134.7M
Accounts Receivable$9.1M
Inventory$0.00
Current Assets$466.4M
LT Investments$179.3M
Property, Plant & Equipment$113.1M
Intangibles$0.00
Non-Current Assets$292.3M
Total Assets$758.8M
Accounts Payable$18.8M
Current Debt$19.1M
Current Liabilities$76.4M
LT Debt$61.4M
Non-Current Liabilities$61.4M
Total Liabilities$137.8M
Total Debt$80.5M
Retained Earnings-$2.69B
Shareholder Equity$620.9M
Shares Outstanding118,133,546

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$117.3M
Investing Cash Flow$66.3M
Financing Cash Flow$33.6M
CapEx-$79.0K
Free Cash Flow-$117.4M
Depreciation & Amort.$2.2M
Stock-Based Comp$13.5M
Acquisitions / Disposals$0.00
Investment Activity$66.4M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$33.6M
Dividends Paid$0.00
Net Change in Cash-$17.5M
Data cached · Meta live · Daily live · Statements live · TTL 24h